The first approved ADC by the FDA is gemtuzumab ozogamycin (GO/Mylotarg) targeting CD33 in 2000 to treat AML (Bross et al., 2001) and was subsequently removed from market due to increased risk of hepatic veno-occlusive disease (VOD) and high mortality (Petersdorf et al., 2013). The gene discussed is CD33; the disease is acute myeloid leukemia.